尊龙凯时

    Development Progress
    Development Progress
    R&D Projects Registration Category Indication/Therapeutic Use Phase I Phase II Phase III Approved
    PUDK-HGF Biological Products Category 1 Rest pain and/or ischemic ulcers in limbs due to severe ischemic disease of the lower extremities
    Remazolam Besylate for Injection New Indication Chemical category 1 Sedation during intensive care unit (ICU)
    PARP Inhibitors Chemical category 1 Ovarian cancer, breast cancer, lung cancer, etc
    BTK Inhibitors Chemical category 1 Chronic spontaneous urticaria
    HW021199 Tablets Chemical category 1 Treatment of idiopathic pulmonary fibrosis
    RFUS-144 Injection Chemical category 1 Treatment of pain and pruritus
    Bai-re-si Pills Chemical category 1 Treatment of stable vitiligo
    Compound Yixie Granules Chemical category 1 Hyperuricemia in the non-acute phase of gout and syndrome of stasis of dampness and turbidness
    LL-50 Injection Chemical category 1 Control of surgical anesthesia and acute pain